Journal article
The IASLC lung cancer staging project: Proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer
R Rami-Porta, V Bolejack, J Crowley, D Ball, J Kim, G Lyons, T Rice, K Suzuki, CF Thomas, WD Travis, YL Wu
Journal of Thoracic Oncology | ELSEVIER SCIENCE INC | Published : 2015
Abstract
Introduction: An international database was collected to inform the 8th edition of the anatomic classification of lung cancer. The present analyses concern its primary tumor (T) component. Methods: From 1999 to 2010, 77,156 evaluable patients, 70,967 with non-small-cell lung cancer, were collected; and 33,115 had either a clinical or a pathological classification, known tumor size, sufficient T information, and no metastases. Survival was measured from date of diagnosis or surgery for clinically and pathologically staged tumors. Tumor-size cutpoints were evaluated by the running log-rank statistics. T descriptors were evaluated in a multivariate Cox regression analysis adjusted for age, gend..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
David Ball has declared ongoing board memberships of Lilly Oncology, Astra Zeneca and Boehring-Ingelheim. John Crowley has declared that his work is fundded by the International Association for the Study of Lung Cancer (IASLC) and has received grants and support to travel from the IASLC. Vanessa Bolejack has declared that her work is currently funded by the International Association for the Study of Lung Cancer (IASLC) and that she has received grants and support to travel and to write and review articles from the IASLC. William D. Travis has declared that he is a current member of the Board of the International Association for the Study of Lung Cancer, but this activity has no financial implications. Yi-Long Wu has declared he currently receives payment for lectures from Roche.